Journal Watch · Frontiers in Immunology · 2026

Case Report: Lupus miliaris disseminatus faciei successfully treated with thalidomide combined with photodynamic therapy: two cases and literature review.

Further studies and controlled trials are warranted to confirm the efficacy and safety of this therapeutic approach.

Feng H, Sun Z, Li H et al.Frontiers in Immunology3 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1724732PMID: 41822486Study type: review / perspective

TL;DR

Further studies and controlled trials are warranted to confirm the efficacy and safety of this therapeutic approach.

Key findings

  • Following this combination therapy, the lesions showed marked resolution, leaving only minimal depressed scars, and no relapse occurred during a 24-month follow-up.
  • These cases suggest that PDT combined with thalidomide may provide an effective option for refractory LMDF, with early intervention potentially minimizing scarring.
  • Further studies and controlled trials are warranted to confirm the efficacy and safety of this therapeutic approach.

What they did

However, data on PDT use in LMDF is limited. Here, we report two young male patients with LMDF presenting with multiple firm red papules on the face, both of whom had previously received four lines of treatment-including antibiotics (minocycline, doxycycline, clarithromycin), topical tacrolimus, and traditional Chinese medicine-without clinical improvement. Both patients subsequently underwent four sessions of 5-aminolevulinic acid-based PDT (5-ALA-PDT) combined with oral thalidomide.

Full abstract (original)

Background: Lupus miliaris disseminatus faciei (LMDF) is a rare granulomatous rosacea characterized by multiple papular eruptions primarily affecting the central face, resulting in both physical discomfort and notable cosmetic concerns. Despite various proposed therapies, the optimal treatment for LMDF remains controversial. Photodynamic therapy (PDT) employs a photosensitizer, light source, and oxygen to generate reactive oxygen species (ROS) that selectively target and destroy abnormal tissue, and it has also been shown to reduce and prevent scar formation.

What they did: However, data on PDT use in LMDF is limited. Here, we report two young male patients with LMDF presenting with multiple firm red papules on the face, both of whom had previously received four lines of treatment-including antibiotics (minocycline, doxycycline, clarithromycin), topical tacrolimus, and traditional Chinese medicine-without clinical improvement. Both patients subsequently underwent four sessions of 5-aminolevulinic acid-based PDT (5-ALA-PDT) combined with oral thalidomide.

Results & conclusions: Following this combination therapy, the lesions showed marked resolution, leaving only minimal depressed scars, and no relapse occurred during a 24-month follow-up. These cases suggest that PDT combined with thalidomide may provide an effective option for refractory LMDF, with early intervention potentially minimizing scarring. Further studies and controlled trials are warranted to confirm the efficacy and safety of this therapeutic approach.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1724732 · PubMed 41822486.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Further studies and controlled trials are warranted to confirm the efficacy and safety of this therapeutic approach.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. However, data on PDT use in LMDF is limited.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1724732. PubMed ID: 41822486. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Feng H, Sun Z, Li H et al.. Case Report: Lupus miliaris disseminatus faciei successfully treated with thalidomide combined with photodynamic therapy: two cases and literature review.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1724732.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/case-report-lupus-miliaris-disseminatus-faciei-successfully-treated-with-724732/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides